FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER
Executive Summary
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
You may also be interested in...
Stockbridge to head Cardio-Renal permanently
Norman Stockbridge is appointed permanent director of the Center for Drug Evaluation & Research's Division of Cardiovascular and Renal Products. Stockbridge has been serving as acting director since Douglas Throckmorton became CDER deputy director in May 2004 (1"The Pink Sheet" April 19, 2004, p. 4). Stockbridge joined FDA in 1991 as a medical officer and was appointed Cardio-Renal division deputy director in 2002...
Stockbridge to head Cardio-Renal permanently
Norman Stockbridge is appointed permanent director of the Center for Drug Evaluation & Research's Division of Cardiovascular and Renal Products. Stockbridge has been serving as acting director since Douglas Throckmorton became CDER deputy director in May 2004 (1"The Pink Sheet" April 19, 2004, p. 4). Stockbridge joined FDA in 1991 as a medical officer and was appointed Cardio-Renal division deputy director in 2002...
CDER appoints deputy director
Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton is appointed to the post on a permanent basis. Throckmorton became acting deputy director in May 2004 after serving as director of the Division of Cardiovascular & Renal Drug Products since 2002 ("1The Pink Sheet" April 19, 2004, p. 4). He is the founding chair of the Drug Safety Oversight Board and chair of CDER's Research Coordinating Committee...